Radiopharm Theranostics Ltd. Reports Dual Clinical Successes and Announces Capital‑Raising Initiative
Radiopharm Theranostics Ltd. (ASX: RAD), a clinical‑stage biopharmaceutical company focused on radiopharmaceuticals for oncology, has announced a series of positive clinical‑trial results that reinforce its pipeline’s potential to address unmet medical needs in advanced solid tumours and brain metastases. The company’s announcement also includes an update on its capital‑raising efforts and the temporary suspension of its shares from ASX quotation.
Clinical‑Trial Highlights
| Date | Source | Key Development |
|---|---|---|
| 22 July 2026 | Nasdaq.com | Radiopharm announced “Positive Trial Updates” for its two lead assets, RAD101 and RAD204, underscoring encouraging data from ongoing studies. |
| 22 July 2026 | GlobeNewswire | In a Phase 1 trial of RAD204, patients with advanced solid tumours that had progressed after immunotherapy achieved a confirmed durable partial response. |
| 22 July 2026 | GlobeNewswire | The Phase 2b study of RAD101, aimed at diagnosing brain metastases, yielded positive results and was highlighted as a significant milestone for the diagnostic arm of the company’s portfolio. |
| 22 July 2026 | Nasdaq.com | Additional details were released regarding the Phase 2b data for RAD101 in participants suspected of recurrence of brain metastases following radiotherapy. |
| 22 July 2026 | Investing.com / de.investing.com | Multiple independent outlets reported on the partial response observed in the RAD204 cancer trial, reinforcing the clinical relevance of the asset. |
These data points collectively suggest that Radiopharm’s radiopharmaceuticals are demonstrating efficacy in both therapeutic and diagnostic roles. The partial responses in RAD204 after immunotherapy and the diagnostic accuracy of RAD101 in detecting brain metastases address critical gaps in oncology treatment and surveillance.
Capital‑Raising Announcement
On 24 July 2026, the Australian Securities Exchange (ASX) issued a market announcement indicating that the trading suspension would be lifted “immediately following the release by RAD of an announcement regarding a capital raising.” The company subsequently issued a detailed proposal:
- Total securities to be issued: 400 million new ordinary shares (option‑expiring 31 July 2029) and 400 million ordinary fully paid shares, with a record date of 23 July 2026.
- Offer closing date: 10 September 2026.
- Issue date: 17 September 2026.
This capital‑raising initiative is aimed at supporting the company’s research, development, and commercialization activities, particularly in light of the recent clinical successes.
Trading Suspension and Reinstatement
On 23 July 2026, Radiopharm requested voluntary suspension of its shares under Listing Rule 17.2. The ASX complied, suspending trading immediately pending the release of the capital‑raising announcement. The suspension was lifted on 24 July 2026 once the company’s announcement was made public, reinstating the company’s quotation on the ASX All Markets.
Market Context
- Recent share performance: As of 20 July 2026, the closing price stood at AUD 0.019, well below the 52‑week low of AUD 0.017 (recorded 9 December 2025).
- Market capitalisation: AUD 67.34 million.
- Price‑earnings ratio: -1.24, reflecting the company’s ongoing clinical‑stage status.
Outlook
Radiopharm Theranostics Ltd. has secured two key clinical milestones within a single trading day, reinforcing confidence in its pipeline of radiopharmaceuticals. The forthcoming capital raise, coupled with the successful suspension and reinstatement of its shares, positions the company to advance its clinical programs and potentially expand into broader oncology indications. Investors and market observers will likely monitor the outcome of the 400‑million‑share offer and the progression of RAD101 and RAD204 through later‑stage trials.
